Stem cell therapies for systemic lupus erythematosus: Current progress and established evidence

Expert Review of Clinical Immunology

Volumn 11, Issue 6, 2015, Pages 763-769

  Wang, Dandan ^a   Sun, Lingyun ^a  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

Author keywords

hematopoietic stem cells; immunomodulation; mesenchymal stem cells; systemic lupus erythematosus; transplantation

Indexed keywords

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOGENEIC MESENCHYMAL STEM CELL TRANSPLANTATION; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CLINICAL TRIAL (TOPIC); HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOMODULATION; MESENCHYMAL STEM CELL TRANSPLANTATION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STEM CELL TRANSPLANTATION; SYSTEMIC LUPUS ERYTHEMATOSUS; ANIMAL; BIOLOGICAL THERAPY; DRUG RESISTANCE; HEMATOPOIETIC STEM CELL; LUPUS ERYTHEMATOSUS, SYSTEMIC; MESENCHYMAL STROMA CELL; PHYSIOLOGY;

ANIMALS; BIOLOGICAL THERAPY; DRUG RESISTANCE; HEMATOPOIETIC STEM CELLS; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MESENCHYMAL STROMAL CELLS; STEM CELL TRANSPLANTATION;

EID: 84929310579     PISSN: 1744666X     EISSN: 17448409     Source Type: Journal    
DOI: 10.1586/1744666X.2015.1037741     Document Type: Review

References (63)

1. Doria A, Gatto M, Zen M, et al. Optimizing outcome in SLE: treating-To-Target and definition of treatment goals. Autoimmun Rev 2014;13:770-7
2. Gatto M, Zen M, Ghirardello A, et al. Emerging and critical issues in the pathogenesis of lupus. Autoimmun Rev 2013;12:523-36
3. Houssiau FA, D'Cruz D, Sangle S, et al. Azathioprine versus mycophenolate mofetil for long-Term immunosuppression in lupus nephritis: results from the Maintain Nephritis Trial. Ann Rheum Dis 2010;69: 2083-9
4. Ginzler EM, Wofsy D, Isenberg D, et al. Nonrenal disease activity following mycophenolate mofetil or intravenous cyclophosphamide as induction treatment for lupus nephritis: findings in a multicenter, prospective, randomized, open-label, parallel-group clinical trial. Arthritis Rheum 2010;62:211-21
5. Costedoat-Chalumeau N, Dunogue-B, Morel N, et al. Hydroxychloroquine: a multifaceted treatment in lupus. Presse Med 2014;43:e167-80
6. Lisnevskaia L, Murphy G, Isenberg D. Systemic lupus erythematosus. Lancet 2014;384:1878-88
7. Navarra SV, Guzman RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 2011;377:721-31
8. Wallace DJ, Kalunian K, Petri MA, et al. Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study. Ann Rheum Dis 2014;73:183-90
9. Petri M, Wallace DJ, Spindler A, et al. Sifalimumab, a human anti-interferon-A monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose-escalation study. Arthritis Rheum 2013;65:1011-21
10. Mu Y, Zhao M, Su G. Stem cell-based therapies for age-related macular degeneration: current status and prospects. Int J Clin Exp Med 2014;7:3843-52
11. Tyndall A. Mesenchymal stem cell treatments in rheumatology: a glass half full?. Nat Rev Rheumatol 2014;10:117-24
12. Marmont AM, van Lint MT, Gualandi F, et al. Autologous marrow stem cell transplantation for severe systemic lupus erythematosus of long duration. Lupus 1997;6:545-8
13. Traynor AE, Barr WG, Rosa RM, et al. Hematopoietic stem cell transplantation for severe and refractory lupus. Analysis after five years and fifteen patients. Arthritis Rheum 2002;46:2917-23
14. Traynor AE, Schroeder J, Rosa RM, et al. Treatment of severe systemic lupus erythematosus with high-dose chemotherapy and haemopoietic stem-cell transplantation: a phase I study. Lancet 2000;356:701-7
15. Burt RK, Traynor A, Statkute L, et al. Nonmyeloablative hematopoietic stem cell transplantation for systemic lupus erythematosus. JAMA 2006;295:527-35
16. Sun L. Stem cell transplantation: progress in Asia. Lupus 2010;19:1468-73
17. Alchi B, Jayne D, Labopin M, et al. Autologous haematopoietic stem cell transplantation for systemic lupus erythematosus: data from the European Group for Blood and Marrow Transplantation registry. Lupus 2013;22: 245-53
18. Furst DE. Stem cell transplantation for autoimmune disease: progress and problems. Curr Opin Rheumatol 2002;14:220-4
19. Su G, Luan Z, Wu F, et al. Long-Term follow-up of autologous stem cell transplantation for severe pediatric systemic lupus erythematosus. Clin Rheumatol 2013;32:1727-34
20. Wada H, Terasako K, Kamiya Y, et al. Immune recovery after autologous PBSC transplantation without in vitro graft manipulation for refractory systemic lupus erythematosus. Bone Marrow Transplant 2011;46:1450-4
21. Alexander T, Thiel A, Rosen O, et al. Depletion of autoreactive immunologic memory followed by autologous hematopoietic stem cell transplantation in patients with refractory SLE induces long-Term remission through de novo generation of a juvenile and tolerant immune system. Blood 2009;113:214-23
22. Zhang L, Bertucci AM, Ramsey-Goldman R, et al. Regulatory T cell (Treg) subsets return in patients with refractory lupus following stem cell transplantation, and TGF-beta-producing CD8+ Treg cells are associated with immunological remission of lupus. J Immunol 2009;183:6346-58
23. Sweeney SE. Hematopoietic stem cell transplant for systemic lupus erythematosus: Interferon regulatory factor 7 activation correlates with the IFN signature and recurrent disease. Lupus 2011;20:975-80
24. Zeher M, Papp G, Szodoray P. Autologous haemopoietic stem cell transplantation for autoimmune diseases. Expert Opin Biol Ther 2011;11:1193-201
25. Jayne D, Passweg J, Marmont A, et al. Autologous stem cell transplantation for systemic lupus erythematosus. Lupus 2004;13:168-76
26. Niu H, Fang G, Tang Y, et al. The function of hematopoietic stem cells is altered by both genetic and inflammatory factors in lupus mice. Blood 2013;121: 1986-94
27. Rosa SB, Voltarelli JC, Chies JA, et al. The use of stem cells for the treatment of autoimmune diseases. Braz J Med Biol Res 2007;40:1579-97
28. Sun LY, Zhou KX, Feng XB, et al. Abnormal surface markers expression on bone marrow CD34+ cells and correlation with disease activity in patients with systemic lupus erythematosus. Clin Rheumatol 2007;26:2073-9
29. Cipriani P, Carubbi F, Liakouli V, et al. Stem cells in autoimmune diseases: Implications for pathogenesis and future trends in therapy. Autoimmun Rev 2013;12:709-16
30. Tyndall A, Saccardi R. Haematopoietic stem cell transplantation in the treatment of severe autoimmune disease: results from phase I/II studies, prospective randomized trials and future directions. Clin Exp Immunol 2005;141:1-9
31. Smith-Berdan S, Gille D, Weissman IL, et al. Reversal of autoimmune disease in lupus-prone New Zealand black/New Zealand white mice by nonmyeloablative transplantation of purified allogeneic hematopoietic stem cells. Blood 2007;110: 1370-8
32. Vanikar AV, Modi PR, Patel RD, et al. Hematopoietic stem cell transplantation in autoimmune diseases: the Ahmedabad experience. Transplant Proc 2007;39:703-8
33. Daikeler T, Hugle T, Farge D, et al. Allogeneic hematopoietic SCT for patients with autoimmune diseases. Bone Marrow Transplant 2009;44:27-33
34. Tyndall A, Gratwohl A. Haemopoietic stem and progenitor cells in the treatment of severe autoimmune diseases. Ann Rheum Dis 1996;55:149-51
35. Sun LY, Zhang HY, Feng XB, et al. Abnormality of bone marrow-derived mesenchymal stem cells in patients with systemic lupus erythematosus. Lupus 2007;16:121-8
36. Nie Y, Lau C, Lie A, et al. Defective phenotype of mesenchymal stem cells in patients with systemic lupus erythematosus. Lupus 2010;19:850-9
37. Li X, Liu L, Meng D, et al. Enhanced apoptosis and senescence of bone-marrow-derived mesenchymal stem cells in patients with systemic lupus erythematosus. Stem Cells Dev 2012;21: 2387-94
38. Gu Z, Tan W, Feng G, et al. Wnt/betacatenin signaling mediates the senescence of bone marrow-mesenchymal stem cells from systemic lupus erythematosus patients through the p53/p21 pathway. Mol Cell Biochem 2014;387:27-37
39. Shi D, Li X, Chen H, et al. High level of reactive oxygen species impaired mesenchymal stem cell migration via over polymerization of F-Actin cytoskeleton in systemic lupus erythematosus. Pathol Biol (Paris) 2014;62(6):382-90
40. Tang Y, Ma X, Zhang H, et al. Gene expression profile reveals abnormalities of multiple signaling pathways in mesenchymal stem cell derived from patients with systemic lupus erythematosus. Clin Dev Immunol 2012;2012:826182
41. Tang Y, Xie H, Chen J, et al. Activated NF-kappaB in bone marrow mesenchymal stem cells from systemic lupus erythematosus patients inhibits osteogenic differentiation through downregulating Smad signaling. Stem Cells Dev 2013;22: 668-78
42. Wang D, Feng X, Lu L, et al. A CD8 T cell/indoleamine 2, 3-dioxygenase axis is required for mesenchymal stem cell suppression of human systemic lupus erythematosus. Arthritis Rheumatol 2014;66:2234-45
43. Feng X, Che N, Liu Y, et al. Restored immunosuppressive effect of mesenchymal stem cells on B cells after OAZ downregulation in patients with systemic lupus erythematosus. Arthritis Rheumatol 2014;66:3413-23
44. Gu F, Molano I, Ruiz P, et al. Differential effect of allogeneic versus syngeneic mesenchymal stem cell transplantation in MRL/lpr and (NZB/NZW) F1 mice. Clin Immunol 2012;145:142-52
45. Carrion F, Nova E, Ruiz C, et al. Autologous mesenchymal stem cell treatment increased T regulatory cells with no effect on disease activity in two systemic lupus erythematosus patients. Lupus 2010;19:317-22
46. Sun L, Akiyama K, Zhang H, et al. Mesenchymal stem cell transplantation reverses multiorgan dysfunction in systemic lupus erythematosus mice and humans. Stem Cells 2009;27:1421-32
47. Zhou K, Zhang H, Jin O, et al. Transplantation of human bone marrow mesenchymal stem cell ameliorates the autoimmune pathogenesis in MRL/lpr mice. Cell Mol Immunol 2008;5:417-24
48. Gu Z, Akiyama K, Ma X, et al. Transplantation of umbilical cord mesenchymal stem cells alleviates lupus nephritis in MRL/lpr mice. Lupus 2010;19: 1502-14
49. Chang JW, Hung SP, Wu HH, et al. Therapeutic effects of umbilical cord blood-derived mesenchymal stem cell transplantation in experimental lupus nephritis. Cell Transplant 2011;20:245-57
50. Choi EW, Shin IS, Park SY, et al. Reversal of serologic, immunologic, and histologic dysfunction in mice with systemic lupus erythematosus by long-Term serial adipose tissue-derived mesenchymal stem cell transplantation. Arthritis Rheum 2012;64: 243-53
51. Liang J, Zhang H, Hua B, et al. Allogenic mesenchymal stem cells transplantation in refractory systemic lupus erythematosus: a pilot clinical study. Ann Rheum Dis 2010;69:1423-9
52. Sun L, Wang D, Liang J, et al. Umbilical cord mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus. Arthritis Rheum 2010;62: 2467-75
53. Wang D, Zhang H, Liang J, et al. Allogeneic mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus: 4 years of experience. Cell Transplant 2013;22: 2267-77
54. Gu F, Wang D, Zhang H, et al. Allogeneic mesenchymal stem cell transplantation for lupus nephritis patients refractory to conventional therapy. Clin Rheumatol 2014;33:1611-19
55. Shi D, Wang D, Li X, et al. Allogeneic transplantation of umbilical cord-derived mesenchymal stem cells for diffuse alveolar hemorrhage in systemic lupus erythematosus. Clin Rheumatol 2012;31: 841-6
56. Li X, Wang D, Liang J, et al. Mesenchymal SCT ameliorates refractory cytopenia in patients with systemic lupus erythematosus. Bone Marrow Transplant 2013;48:544-50
57. Wang D, Li J, Zhang Y, et al. Umbilical cord mesenchymal stem cell transplantation in active and refractory systemic lupus erythematosus: a multicenter clinical study. Arthritis Res Ther 2014;16:R79
58. Li K, Han Q, Yan X, et al. Not a process of simple vicariousness, the differentiation of human adipose-derived mesenchymal stem cells to renal tubular epithelial cells plays an important role in acute kidney injury repairing. Stem Cells Dev 2010;19:1267-75
59. Ji S, Guo Q, Han Y, et al. Mesenchymal stem cell transplantation inhibits abnormal activation of Akt/GSK3beta signaling pathway in T cells from systemic lupus erythematosus mice. Cell Physiol Biochem 2012;29:705-12
60. Ma X, Che N, Gu Z, et al. Allogenic mesenchymal stem cell transplantation ameliorates nephritis in lupus mice via inhibition of B-cell activation. Cell Transplant 2013;22:2279-90
61. Schena F, Gambini C, Gregorio A, et al. Interferon-gamma-dependent inhibition of B cell activation by bone marrow-derived mesenchymal stem cells in a murine model of systemic lupus erythematosus. Arthritis Rheum 2010;62:2776-86
62. Wang D, Akiyama K, Zhang H, et al. Double allogenic mesenchymal stem cells transplantations could not enhance therapeutic effect compared with single transplantation in systemic lupus erythematosus. Clin Dev Immunol 2012;2012:273291
63. Blommestein HM, Verelst SG, Huijgens PC, et al. Real-world costs of autologous and allogeneic stem cell transplantations for haematological diseases: a multicentre study. Ann Hematol 2012;91:1945-52